מדינה: מלזיה
שפה: אנגלית
מקור: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)
TRIAZOLAM
DUOPHARMA (M) SDN. BHD.
TRIAZOLAM
100Tablet Tablets; 500Tablet Tablets
DUOPHARMA (M) SDN. BHD.
_Consumer Medication Information Leaflet (RIMUP) _ 1 INZOLAM TABLET Triazolam 0.25mg WHAT IS IN THE LEAFLET? 1. What INZOLAM is used for 2. How INZOLAM works 3. Before you use INZOLAM 4. How to use INZOLAM 5. While you are using it 6. Side effects 7. Storage and Disposal of INZOLAM 8. Product Description 9. Manufacturer and Product Registration Holder 10. Date of Revision WHAT INZOLAM IS USED FOR Inzolam is used to treat sleeping problems, also called insomnia. It should be used for short-term treatment only. Continuous long-term use is not recommended unless advised by your doctor. The use of benzodiazepines may lead to dependence on the medicine. Your doctor, however, may have prescribed this medicine for another reason. Ask your doctor if you have questions about why it has been prescribed for you. HOW INZOLAM WORKS Inzolam belongs to a group of medicines called short-acting benzodiazepines. They are thought to work by their action on brain chemicals. BEFORE YOU USE INZOLAM _When you must not take it _ Do not take Inzolam if you: have an allergy to triazolam, any other benzodiazepine, or any of the ingredients listed at the end of this leaflet. some symptoms of an allergic reaction include skin rash, itching, shortness of breath or swelling of the face, lips or tongue, which may cause difficulty in swallowing or breathing. are suffering from depression or are taking nefazodone, a medicine used for treating depression. are taking medicines to treat fungal infections (ketoconazole and itraconazole). have severe and chronic lung disease. suffer from a disease that causes severe muscle weakness known as myasthenia gravis. are pregnant or plan to become pregnant. Do not use in future episodes of insomnia unless you are sure you are not pregnant. are breastfeeding or plan to breast-feed. Do not take it after the expiry date printed on the pack. If you take it after the expiry date has passed, it may not work as well. Do not take it if the packaging is torn or shows signs of tampering. קרא את המסמך השלם
[DUOPHARMA (M) SDN BHD] Page 1 of 2 [REVISION DATE: 12.06.2019] INZOLAM TABLET 0.25 MG DESCRIPTION: An oval, scored tablet blue in colour with markings ‘DUO 861’ and ‘d/d’. COMPOSITION: Each tablet contains Triazolam 0.25mg. PHARMACODYNAMICS: Triazolam is a potent short-acting benzodiazepines with general properties similar to those of diazepam. PHARMACOKINETICS: Triazolam is rapidly and nearly completely absorbed from the gastrointestinal tract, peak plasma concentrations being achieved within 2 hours of administration by mouth. Triazolam has a plasma elimination half-life ranging from 1.5 to 5.5 hours. It is reported to be about 89% bound to plasma proteins. Hydroxylation of Triazolam in the liver is mediated by the cytochrome P450 isozyme CYP3A4. Triazolam is excreted in the urine mainly in the form of its conjugated metabolites with only small amounts appearing unchanged. INDICATION: Inzolam is useful in the management of patients with transient and short term insomnia. It is also useful as a short term adjunctive treatment in the management of selected patients with long-term insomnia. RECOMMENDED DOSAGE: It is important to individualized dosage of Triazolam in patients within various population groups in order to obtain maximum therapeutic effect while using the smallest effective dose. The recommended dose for most adults is 0.25 mg before retiring. A dose of 0.125 mg may be found sufficient for some patients (e.g. low body weight). A dose of 0.5 mg should be used only for exceptional patients who do not respond adequately to a trial of a lower dose since the risk of several adverse reactions increases with the size of the dose administered. A dose of 0.5mg should not be exceeded. In geriatric and/or debilitated patients the recommended dosage range is 0.125 mg to 0.25 mg. Therapy should be initiated at 0.125 mg in this group and the 0.25 mg dose should be used only for exceptional patients who do not respond to a trial of the lower dose. A total dose of 0.25 mg should not be exceeded in these pati קרא את המסמך השלם